secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0000950170-22-026669
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix appoints Lawrence T. Kennedy to Board of Directors, effective Jan 3, 2023
--------------------------------------------------------------------------------

- Kennedy appointed to Board and Audit Committee, effective Jan 3, 2023.
- He brings 20+ years healthcare operating, finance, and investment experience; managing partner/CEO of Westwood Management.
- Initial equity grant of $375K (50% NQSOs, 50% RSUs) plus prorated annual grant of $46,411 in RSUs.
- Senior Mgmt Bonus to Equity Plan amended: Multiplier reduced from 4 to 3, and Company may limit election by percentage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022026669/0000950170-22-026669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022026669/bdsx-20221214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer